Ergot-derived Dopamine agonists (bromocriptine, pergolide, cabergoline) are NOT recommended as a first-line treatment option for Parkinson's disease and should be considered BLACK.
Ergot-derived Dopamine agonists (bromocriptine, pergolide, cabergoline) should only be considered as an adjunct to levodopa in Parkinson's disease patients:
- who have developed dyskinesia or motor fluctuations despite optimal levodopa therapy AND
- whose symptoms are not adequately controlled with a non-ergot derived dopamine agonist (pramipexole, ropinirole).
NOT for primary care prescribing, although all RED drug prescribing should be recorded on the patient's practice records. On-going toxicity monitoring is required.
